- Price
- $76.32
- Day
- -0.77%
- Mkt Cap
- $9.17B
- 52W Range
- $69.56 – $82.08
- Volume
- 1.10M
- Beta
- 0.47
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company believes scientifically driven collaborations will play an increasingly important role in advancing the next generation of ADC innovation.
Read full article
The current market is built around AI. We are seeing more and more signs that the market is getting exhausted by the AI hype. In this setting, I am extra skeptical about high-risk and “too good to be true” yield instruments.
Read full article
California State Teachers Retirement System grew its position in shares of Agree Realty Corporation (NYSE: ADC) by 33.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 140,189 shares of the real estate investment trust's stock after buying an additional 35,124
Read full article
Retirees heading into fall want two things from an income portfolio: a check that shows up every 30 days, and a dividend that will not be cut.
Read full article
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug
Read full article
ADC remains a hold due to its high valuation despite outstanding portfolio quality and defensive tenant mix. ADC's portfolio boasts 99.8% occupancy, 66% investment-grade tenants, and leading rent PSF, underpinning its sector outperformance. Recent acquisitions averaged a 7% cap rate with 11.2-year WALT, supporting raised AFFO/share growth guidance to nearly 6% for 2024.
Read full article
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J.
Read full article
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs). NECs are aggressive malignancies that frequently express DLL3. There are no available targeted therapies.
Read full article
ADC delivered a strong Q2 with record acquisition activity, robust AFFO growth, and raised guidance across key metrics. ADC leverages a sector-leading cost of capital, maintaining a 150 basis point investment spread and a conservative balance sheet with net debt/EBITDA at 3.7x. External growth is fueled by aggressive equity issuance, but current valuation offers less yield than peers and is comparable to risk-free assets.
Read full article
Agree Realty NYSE: ADC reported record second-quarter investment activity and raised its full-year outlook, citing strong acquisition, development and portfolio performance.
Read full article
Agree Realty Corporation (ADC) Q2 2026 Earnings Call Transcript
Read full article
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.14 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to FFO of $1.06 per share a year ago.
Read full article